调脂治疗对高脂血症合并糖耐量异常临床疗效观察.docVIP

调脂治疗对高脂血症合并糖耐量异常临床疗效观察 　　【摘要】目的 观察不同调脂治疗方案对高脂血症合并糖耐量异常的疗效及安全性．方法 将157例高脂血症合并糖耐量异常的患者随机分为三组，即血脂康组，辛伐他汀组和生活方式干预组（对照组），治疗6个月后观察疗效。结果 血脂康组及辛伐他汀组治疗6个月后TC、TG、LDL-C水平与治疗前对比有显著性降低，HDL-C显著升高（Ｐ0.05）。血脂康组FPG、2hPG及HbAIc与治疗前相比差异有统计学意义（Ｐ0.05）。结论 血脂康更适合高脂血症合并糖耐量异常患者，能有效降低高脂血症及改善糖耐量异常，且安全性良好，值得在临床推广。 　　【关键词】调脂治疗 高脂血症糖耐量异常 　　中图分类号：R589.21 文献标识码：A 文章编号：1005-0515（2011）7-054-03 　　Clinical observation on lipid-regulating treatment for patients with hyperlipemia and impaired glucose tolerance 　　XIE Yuanling1 ZHOU Zhiheng2 HUANG Yanping1 　　(1. General practice department , the second people,s hospital of Yuexie District , Guangzhou 510180,China. 　　2. School of public health and general practice , Guangzhou medical college . Guangzhou 510000 China.) 　　【Abstract】Objective The study was conducted to investigate the clinical efficacy and safety of different ways of lipid-modulating treatment for patients with hyperlipemia and impaired glucose tolerance. Method 157 cases of patients with hyperlipemia and impaired glucose tolerance were randomly allocated to xuezhikang group , simvastatin group and lifestyle intervention group respectively . the therapeutic results were tested 6 months after treatment. Results After 6 months treatment , the lipid profile was evidently improved in xuezhikang group and simvastatin group . level of total cholesterol ( TC ), triglyceridemia ( TG ) , low-density lipoprotein cholesterol ( LDL-C ) were significantly reduced and high-density lipoprotein cholesterol ( HDL-C ) increased significantly （Ｐ0.05）. The level of fasting plasma glucose ( FPG ) , 2 hours plasma glucose ( 2hPG ) and glycohemoglobin ( HbAIc ) decreased obviously in xuezhikang group （P0.05）. Conclusions These results indicated that xuezhikang is effective in reducing hyperlipemia , improving impaired glucose tolerance , and it is safe . Therefore , xuezhikang is much more suitable for the treatment of patients with hyperlipemia and impaired glucose tolerance , it is worth to be widely used